ABUS – Arbutus Biopharma Corporation
Float Short %
9.02
Margin Of Safety %
Put/Call OI Ratio
0.5
EPS Next Q Diff
-0.02
EPS Last/This Y
0.12
EPS This/Next Y
0.03
Price
4.28
Target Price
6
Analyst Recom
1
Performance Q
-4.04
Upside
-213.3%
Beta
0.71
Ticker: ABUS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | ABUS | 4.06 | 0.45 | 0.01 | 31715 |
| 2026-01-26 | ABUS | 4.08 | 0.44 | 0.02 | 32052 |
| 2026-01-27 | ABUS | 4.16 | 0.44 | 0.00 | 32291 |
| 2026-01-28 | ABUS | 4.14 | 0.52 | 0.01 | 28539 |
| 2026-01-29 | ABUS | 4.12 | 0.52 | 0.01 | 28682 |
| 2026-01-30 | ABUS | 4.15 | 0.52 | 0.11 | 28847 |
| 2026-02-02 | ABUS | 4.39 | 0.52 | 0.74 | 28823 |
| 2026-02-03 | ABUS | 4.11 | 0.52 | 1.12 | 30248 |
| 2026-02-05 | ABUS | 3.66 | 0.52 | 0.05 | 30379 |
| 2026-02-09 | ABUS | 4.06 | 0.53 | 0.01 | 30628 |
| 2026-02-10 | ABUS | 4.16 | 0.51 | 0.12 | 31164 |
| 2026-02-11 | ABUS | 4.17 | 0.51 | 0.03 | 31257 |
| 2026-02-12 | ABUS | 4.03 | 0.51 | 0.18 | 31278 |
| 2026-02-13 | ABUS | 3.99 | 0.51 | 0.02 | 31324 |
| 2026-02-17 | ABUS | 4.18 | 0.51 | 0.05 | 31404 |
| 2026-02-18 | ABUS | 4.13 | 0.50 | 0.47 | 31644 |
| 2026-02-19 | ABUS | 4.23 | 0.50 | 0.24 | 32692 |
| 2026-02-20 | ABUS | 4.28 | 0.50 | 0.05 | 32712 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | ABUS | 4.06 | 43.9 | - | -0.26 |
| 2026-01-26 | ABUS | 4.07 | 43.9 | - | -0.26 |
| 2026-01-27 | ABUS | 4.16 | 43.9 | - | -0.26 |
| 2026-01-28 | ABUS | 4.14 | 43.9 | - | -0.26 |
| 2026-01-29 | ABUS | 4.12 | 43.9 | - | -0.26 |
| 2026-01-30 | ABUS | 4.15 | 43.9 | - | -0.26 |
| 2026-02-02 | ABUS | 4.39 | 43.9 | - | -0.26 |
| 2026-02-03 | ABUS | 4.11 | 43.9 | - | -0.26 |
| 2026-02-04 | ABUS | 3.87 | 43.9 | - | -0.26 |
| 2026-02-05 | ABUS | 3.66 | 43.9 | - | -0.26 |
| 2026-02-06 | ABUS | 3.85 | 43.9 | - | -0.26 |
| 2026-02-09 | ABUS | 4.05 | 43.9 | - | -0.26 |
| 2026-02-10 | ABUS | 4.17 | 43.9 | - | -0.26 |
| 2026-02-11 | ABUS | 4.16 | 43.9 | - | -0.26 |
| 2026-02-12 | ABUS | 4.01 | 43.9 | - | -0.26 |
| 2026-02-13 | ABUS | 3.98 | 43.9 | - | -0.26 |
| 2026-02-17 | ABUS | 4.18 | 43.9 | - | -0.26 |
| 2026-02-18 | ABUS | 4.13 | 43.9 | - | -0.26 |
| 2026-02-19 | ABUS | 4.24 | 43.9 | - | -0.26 |
| 2026-02-20 | ABUS | 4.28 | 43.9 | - | -0.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | ABUS | 0.00 | 0.25 | 8.34 |
| 2026-01-26 | ABUS | 0.00 | -0.07 | 8.34 |
| 2026-01-27 | ABUS | 0.00 | -0.07 | 8.34 |
| 2026-01-28 | ABUS | 0.00 | -0.07 | 8.69 |
| 2026-01-29 | ABUS | 0.00 | -0.07 | 8.69 |
| 2026-01-30 | ABUS | 0.00 | -0.07 | 8.69 |
| 2026-02-02 | ABUS | 0.00 | -0.05 | 8.69 |
| 2026-02-03 | ABUS | 0.00 | -0.05 | 8.69 |
| 2026-02-04 | ABUS | 0.00 | -0.05 | 8.69 |
| 2026-02-05 | ABUS | 0.00 | -0.05 | 8.69 |
| 2026-02-06 | ABUS | 0.00 | -0.05 | 8.69 |
| 2026-02-09 | ABUS | 0.00 | -0.23 | 8.70 |
| 2026-02-10 | ABUS | 0.00 | -0.23 | 8.70 |
| 2026-02-11 | ABUS | 0.00 | -0.23 | 9.02 |
| 2026-02-12 | ABUS | 0.00 | -0.23 | 9.02 |
| 2026-02-13 | ABUS | 0.00 | -0.23 | 9.02 |
| 2026-02-17 | ABUS | 0.00 | -0.71 | 9.02 |
| 2026-02-18 | ABUS | 0.00 | -0.71 | 9.02 |
| 2026-02-19 | ABUS | 0.00 | -0.71 | 9.02 |
| 2026-02-20 | ABUS | 0.00 | -0.71 | 9.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.06
Avg. EPS Est. Next Quarter
-0.06
Insider Transactions
Institutional Transactions
-0.71
Beta
0.71
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
27
Growth Score
32
Sentiment Score
70
Actual DrawDown %
34.2
Max Drawdown 5-Year %
-63.4
Target Price
6
P/E
Forward P/E
PEG
P/S
56.21
P/B
10.59
P/Free Cash Flow
EPS
-0.22
Average EPS Est. Cur. Y
-0.26
EPS Next Y. (Est.)
-0.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-289.45
Relative Volume
0.86
Return on Equity vs Sector %
-83.6
Return on Equity vs Industry %
-66.2
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Arbutus Biopharma CorporationSector: Healthcare
Industry: Biotechnology
Employees: 44
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today
news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance
stock history ABUS – Arbutus Biopharma Corporation invest stock market
stock prices ABUS premarket after hours
ticker ABUS fair value insiders trading